Why Shares of Adaptimmune Therapeutics Jumped Tuesday

The company bulks up its pipeline by regaining the rights to two of its clinical programs.

Related Keywords

,Genentech ,Drug Administration ,Glaxosmithkline ,Adaptimmune Therapeutics ,Specific Peptide Enhanced Affinity Receptor ,Investigational New Drug Application ,Biologics Licensing Application ,